Correlation
The correlation between APLS and ABBV is 0.40, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
APLS vs. ABBV
Compare and contrast key facts about Apellis Pharmaceuticals, Inc. (APLS) and AbbVie Inc. (ABBV).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: APLS or ABBV.
Performance
APLS vs. ABBV - Performance Comparison
Loading data...
Key characteristics
APLS:
-1.09
ABBV:
0.83
APLS:
-1.75
ABBV:
1.21
APLS:
0.79
ABBV:
1.19
APLS:
-0.71
ABBV:
1.17
APLS:
-1.72
ABBV:
2.66
APLS:
33.78%
ABBV:
9.07%
APLS:
53.78%
ABBV:
28.28%
APLS:
-82.47%
ABBV:
-45.09%
APLS:
-81.86%
ABBV:
-13.31%
Fundamentals
APLS:
$2.19B
ABBV:
$327.88B
APLS:
-$1.75
ABBV:
$2.34
APLS:
2.82
ABBV:
5.72
APLS:
13.32
ABBV:
230.90
APLS:
$775.84M
ABBV:
$57.37B
APLS:
$643.52M
ABBV:
$44.44B
APLS:
-$176.07M
ABBV:
$16.36B
Returns By Period
In the year-to-date period, APLS achieves a -46.94% return, which is significantly lower than ABBV's 6.70% return.
APLS
-46.94%
-11.87%
-50.10%
-58.45%
-25.80%
-12.86%
N/A
ABBV
6.70%
-4.61%
3.65%
23.40%
12.26%
19.77%
15.54%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
APLS vs. ABBV — Risk-Adjusted Performance Rank
APLS
ABBV
APLS vs. ABBV - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Apellis Pharmaceuticals, Inc. (APLS) and AbbVie Inc. (ABBV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
APLS vs. ABBV - Dividend Comparison
APLS has not paid dividends to shareholders, while ABBV's dividend yield for the trailing twelve months is around 3.43%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
APLS Apellis Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
ABBV AbbVie Inc. | 3.43% | 3.49% | 3.82% | 3.49% | 3.84% | 4.41% | 4.83% | 3.89% | 2.65% | 3.64% | 3.41% | 2.54% |
Drawdowns
APLS vs. ABBV - Drawdown Comparison
The maximum APLS drawdown since its inception was -82.47%, which is greater than ABBV's maximum drawdown of -45.09%. Use the drawdown chart below to compare losses from any high point for APLS and ABBV.
Loading data...
Volatility
APLS vs. ABBV - Volatility Comparison
Apellis Pharmaceuticals, Inc. (APLS) has a higher volatility of 15.97% compared to AbbVie Inc. (ABBV) at 9.85%. This indicates that APLS's price experiences larger fluctuations and is considered to be riskier than ABBV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
APLS vs. ABBV - Financials Comparison
This section allows you to compare key financial metrics between Apellis Pharmaceuticals, Inc. and AbbVie Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
APLS vs. ABBV - Profitability Comparison
APLS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Apellis Pharmaceuticals, Inc. reported a gross profit of 132.44M and revenue of 166.80M. Therefore, the gross margin over that period was 79.4%.
ABBV - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, AbbVie Inc. reported a gross profit of 11.20B and revenue of 13.34B. Therefore, the gross margin over that period was 83.9%.
APLS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Apellis Pharmaceuticals, Inc. reported an operating income of -83.33M and revenue of 166.80M, resulting in an operating margin of -50.0%.
ABBV - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, AbbVie Inc. reported an operating income of 3.73B and revenue of 13.34B, resulting in an operating margin of 28.0%.
APLS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Apellis Pharmaceuticals, Inc. reported a net income of -92.23M and revenue of 166.80M, resulting in a net margin of -55.3%.
ABBV - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, AbbVie Inc. reported a net income of 1.29B and revenue of 13.34B, resulting in a net margin of 9.6%.